These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9703286)

  • 21. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
    Santos AM; Sousa H; Portela C; Pereira D; Pinto D; Catarino R; Rodrigues C; Araújo AP; Lopes C; Medeiros R
    Biochem Biophys Res Commun; 2006 Feb; 340(1):256-62. PubMed ID: 16364249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective.
    Berger K; Fischer T; Szucs TD
    Eur J Cancer; 1998 Nov; 34(12):1894-901. PubMed ID: 10023312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.
    Muggia FM; Braly PS; Brady MF; Sutton G; Niemann TH; Lentz SL; Alvarez RD; Kucera PR; Small JM
    J Clin Oncol; 2000 Jan; 18(1):106-15. PubMed ID: 10623700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.
    Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Renody N; Mularoni E; Soubrane C; Weil M; Mortier N; Khayat D
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-38-S2-40. PubMed ID: 9045335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
    Atkins CD
    J Natl Cancer Inst; 2000 Sep; 92(17):1446-7. PubMed ID: 10974091
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
    Tecza K; Pamula-Pilat J; Kolosza Z; Radlak N; Grzybowska E
    J Exp Clin Cancer Res; 2015 Jan; 34(1):2. PubMed ID: 25591549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
    Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
    Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
    El-Husseiny K; Motawei H; Ali MS
    Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.
    Neymark N; Gorlia T; Adriaenssen I; Baron B; Piccart M
    Pharmacoeconomics; 2002; 20(7):485-97. PubMed ID: 12093304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
    Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative pharmaco-economic analysis of docetaxel with cisplatin and cyclophosphamide with cisplatin in first-line chemotherapy of advanced ovarian cancer].
    Gorbunova VA; Khokhlova SV; Komarova BP; Orel NF; Besova NS
    Vopr Onkol; 2002; 48(6):695-9. PubMed ID: 12530266
    [No Abstract]   [Full Text] [Related]  

  • 39. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
    Markman M
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy for ovarian cancer.
    Parmar MK; Sandercock J
    N Engl J Med; 1996 May; 334(19):1268-9; author reply 1270. PubMed ID: 8606729
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.